1. 278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer. (10th December 2020) Authors: Blumenschein, George; Devarakonda, Siddhartha; Johnson, Melissa; Moreno, Victor; Gainor, Justin; Edelman, Martin; Heymach, John; Govindan, Ramaswamy; Bachier, Carlos; Spéville, Bernard Doger de; Frigault, Matthew; Olszanski, Anthony; Lam, Vincent; Hyland, Natalie; Navenot, Jean-Marc; Fayngerts, S... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer. (9th November 2020) Authors: Blumenschein, George; Devarakonda, Siddhartha; Johnson, Melissa; Moreno, Victor; Gainor, Justin; Edelman, Martin; Heymach, John; Govindan, Ramaswamy; Bachier, Carlos; Spéville, Bernard Doger de; Frigault, Matthew; Olszanski, Anthony; Lam, Vincent; Hyland, Natalie; Navenot, Jean-Marc; Fayngerts, S... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A303 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma. (9th November 2020) Authors: Milhem, Mohammed; Zakharia, Yousef; Davar, Diwakar; Buchbinder, Elizabeth; Medina, Theresa; Daud, Adil; Ribas, Antoni; Niu, Jiaxin; Gibney, Geoffrey; Margolin, Kim; Olszanski, Anthony; Mehmi, Inderjit; Sato, Takami; Shaheen, Montaser; Morris, Aaron; Mauro, David; Campbell, Katie; Kelley, Heather;... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 367 A phase 1/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with atezolizumab in patients with advanced solid tumors. (9th November 2020) Authors: Luke, Jason; Janku, Filip; Olszanski, Anthony; Leach, Kevin; Iyer, Radhakrishnan; Abbas, Atif Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2. (10th December 2020) Authors: Powderly, John; Carthon, Bradley; Ernstoff, Marc; Olszanski, Anthony; Wrangle, John; Shields, Anthony; Piha-Paul, Sarina; Curtis, Kelly; Bidollari, Ilda; Du, Yangchun; Sun, Lei; Putiri, Emily; Wang, Yan; Losey, Heather; Dezube, Bruce; Dezube, Bruce; Vaishampayan, Ulka Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2. (9th November 2020) Authors: Powderly, John; Carthon, Bradley; Ernstoff, Marc; Olszanski, Anthony; Wrangle, John; Shields, Anthony; Piha-Paul, Sarina; Curtis, Kelly; Bidollari, Ilda; Du, Yangchun; Sun, Lei; Putiri, Emily; Wang, Yan; Losey, Heather; Dezube, Bruce; Dezube, Bruce; Vaishampayan, Ulka Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A398 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients. (9th November 2020) Authors: El-Khoueiry, Anthony; Thomas, Jacob; Olszanski, Anthony; Azad, Nilofer; Bender, Lewis; Walters, Ian; Whalen, Giles; Hanna, Diana; Ingham, Matthew; Siu, Lilian Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A250 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients. (9th November 2020) Authors: El-Khoueiry, Anthony; Thomas, Jacob; Olszanski, Anthony; Azad, Nilofer; Bender, Lewis; Walters, Ian; Whalen, Giles; Hanna, Diana; Ingham, Matthew; Siu, Lilian Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A436 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). Issue 2 (December 2015) Authors: Long, Georgina; Dummer, Reinhard; Ribas, Antoni; Puzanov, Igor; Michielin, Olivier; VanderWalde, Ari; Andtbacka, Robert; Cebon, Jonathan; Fernandez, Eugenio; Malvehy, Josep; Olszanski, Anthony; Gajewski, Thomas; Kirkwood, John; Kuznetsova, Olga; Chen, Lisa; Kaufman, David; Chou, Jeffrey; Hodi, F Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. Issue 1 (December 2016) Authors: Zibelman, Matthew; Pollak, Natasha; Olszanski, Anthony Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗